ANDA 84282, held by Hikma Pharmaceuticals. Dexamethasone Sodium Phosphate.
As of Nov 21, 2026, ANDA 84282 (Dexamethasone Sodium Phosphate), held by Hikma Pharmaceuticals, was first approved by FDA on Jul 15, 1975, with 28 approved supplements and 0 published complete response letters.
INDICATIONS A. Intravenous or intramuscular administration. When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 15, 1975 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dexamethasone Sodium PhosphateEQ 4MG PHOSPHATE/ML · injectable;injection | Dexamethasone Sodium Phosphate | Rx |
| Jun 5, 2024 | Supplement 59Labeling · Standard review | Approved | None posted |
| Jul 29, 2020 | Supplement 48Labeling · Standard review | Approved | None posted |
| Oct 25, 2016 | Supplement 46Labeling · Standard review | Approved | None posted |
| Jul 11, 2000 | Supplement 44Manufacturing | Approved | None posted |
| Sep 7, 1999 | Supplement 43Manufacturing | Approved | None posted |
| Dec 1, 1998 | Supplement 42Manufacturing | Approved | None posted |
| Jun 16, 1998 | Supplement 37Manufacturing | Approved | None posted |
| Jun 12, 1998 | Supplement 39Manufacturing | Approved | None posted |
| May 7, 1998 | Supplement 38Manufacturing | Approved | None posted |
| Feb 15, 1995 | Supplement 35Labeling | Approved | None posted |
| Jan 5, 1995 | Supplement 36Manufacturing | Approved | None posted |
| Jan 27, 1994 | Supplement 34Labeling | Approved | None posted |
| Aug 28, 1992 | Supplement 33Manufacturing | Approved | None posted |
| Dec 31, 1991 | Supplement 32Labeling | Approved | None posted |
| Oct 28, 1991 | Supplement 31Labeling | Approved | None posted |
| Jun 12, 1991 | Supplement 29Labeling | Approved | None posted |
| Jun 12, 1991 | Supplement 27Manufacturing | Approved | None posted |
| Oct 5, 1989 | Supplement 28Manufacturing | Approved | None posted |
| Mar 15, 1989 | Supplement 26Labeling | Approved | None posted |
| Feb 17, 1989 | Supplement 25Labeling | Approved | None posted |
| Sep 7, 1988 | Supplement 24Labeling | Approved | None posted |
| Jan 11, 1988 | Supplement 19Manufacturing | Approved | None posted |
| Jan 11, 1988 | Supplement 18Manufacturing | Approved | None posted |
| Jan 11, 1988 | Supplement 17Manufacturing | Approved | None posted |
| Oct 22, 1985 | Supplement 21Manufacturing | Approved | None posted |
| Dec 7, 1984 | Supplement 16Manufacturing | Approved | None posted |
| Feb 17, 1983 | Supplement 15Manufacturing | Approved | None posted |
| Feb 17, 1983 | Supplement 14Manufacturing | Approved | None posted |
| Jul 15, 1975 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters